Bicara Therapeutics Inc. BCAX
Bicara Therapeutics Inc. (Nasdaq: BCAX) is an oncology drug developer. Its lead program, ficerafusp alfa, is in Phase 3 for 1L recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (FORTIFI-HN01). Its next catalyst on record is ficerafusp alfa: Data presentation from cohorts (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ficerafusp alfa — Data presentation from cohorts (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ficerafusp alfa | 1L R/M HPV-negative HNSCC | antibody | Phase 3 |
Recent results and decisions
- Mar 30, 2026started Initiated Phase 3 portion of pivotal Phase 2/3 FORTIFI-HN01 at selected 1500mg weekly dose; substantial enrollment expected by end of 2026.
Initiated Phase 3 of the FORTIFI-HN01 study, and expect to be substantially enrolled by the end of the year.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.